Shares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets